JP2005518350A5 - - Google Patents

Download PDF

Info

Publication number
JP2005518350A5
JP2005518350A5 JP2003542219A JP2003542219A JP2005518350A5 JP 2005518350 A5 JP2005518350 A5 JP 2005518350A5 JP 2003542219 A JP2003542219 A JP 2003542219A JP 2003542219 A JP2003542219 A JP 2003542219A JP 2005518350 A5 JP2005518350 A5 JP 2005518350A5
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
group
following formula
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003542219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518350A (ja
Filing date
Publication date
Priority claimed from DE10154689A external-priority patent/DE10154689A1/de
Application filed filed Critical
Publication of JP2005518350A publication Critical patent/JP2005518350A/ja
Publication of JP2005518350A5 publication Critical patent/JP2005518350A5/ja
Pending legal-status Critical Current

Links

JP2003542219A 2001-11-09 2002-11-04 置換アミノケトン化合物 Pending JP2005518350A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10154689A DE10154689A1 (de) 2001-11-09 2001-11-09 Substituierte Aminoketonverbindungen
PCT/EP2002/012288 WO2003040174A2 (en) 2001-11-09 2002-11-04 Substituted amino ketone compounds

Publications (2)

Publication Number Publication Date
JP2005518350A JP2005518350A (ja) 2005-06-23
JP2005518350A5 true JP2005518350A5 (https=) 2006-01-05

Family

ID=7704919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003542219A Pending JP2005518350A (ja) 2001-11-09 2002-11-04 置換アミノケトン化合物

Country Status (4)

Country Link
EP (1) EP1442049A2 (https=)
JP (1) JP2005518350A (https=)
DE (1) DE10154689A1 (https=)
WO (1) WO2003040174A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN1784220B (zh) * 2003-05-05 2011-08-03 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1961416B1 (en) 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06003951A (es) 2003-10-07 2006-06-27 Renovis Inc Derivados de amida como ligandos del canal de ion y composiciones farmaceuticas y sus metodos de uso.
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
AU2007235876A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
CA2795513A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917909D0 (en) * 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
NZ519146A (en) * 1999-11-03 2004-02-27 Albany Molecular Res Inc 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
EP1130022B1 (en) * 2000-02-29 2009-07-22 Universita Degli Studi di Firenze 3-Aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries containing them
AU2001269769A1 (en) * 2000-06-07 2001-12-17 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids

Similar Documents

Publication Publication Date Title
JP2005518350A5 (https=)
JP5105297B2 (ja) Ｐｐａｒ活性調節剤
JP4318087B2 (ja) アミノカルボン酸誘導体およびその医薬用途
ES2259713T3 (es) Beta-amino tetrahidroimidazo(1,2-a)pirazinas y tetrahidrotriazolo (4,3-a)pirazinas como inhibidores de dipeptidil peptidasa para el tratamiento o prevencion de diabetes.
JP6627835B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
CN114292190A (zh) 丁二醇的中链脂肪酸酯，其组合物、口服制剂及其应用方法
BRPI0906094B1 (pt) composto
JP2005272321A (ja) 含窒素複素環化合物およびその医薬用途
JPH08508720A (ja) ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物
JP2020534274A (ja) 脳損傷を治療するための組成物及び方法
CN116327950A (zh) 组合物用于治疗神经退行性疾病的神经精神症状的用途
US20140342989A1 (en) Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
KR102425709B1 (ko) Dp 길항제
CN103269584B (zh) 用于治疗创伤后应激障碍的方法
JP4817281B2 (ja) パーキンソン病治療剤
WO2024096066A1 (ja) 中枢神経系損傷疾患を処置または予防するための環状ペプチド誘導体組成物
CN1311677A (zh) 顽固性癫痫的治疗剂或预防剂
WO2023224128A1 (ja) 線維症の治療又は予防のための医薬組成物
CN114075123B (zh) 苄胺类衍生物及其制备方法与用途
JP6642422B2 (ja) 環状アミン誘導体及びその医薬用途
WO2006095822A1 (ja) スルホンアミド化合物およびその医薬
EP4613283A1 (en) Cyclic peptide derivative composition for treating or preventing neuropathic pain and/or inflammatory pain
JP2007001946A (ja) ピロリジン誘導体
RU2775783C2 (ru) Способы лечения посттравматического стрессового расстройства